2017 American Transplant Congress
A Novel 3-Dimensional Culture System Enables In Vitro Study of Human Bone Marrow Plasma Cells.
Purpose: Historically, in vitro study of human plasma cells (PCs) has been greatly limited by their short survival (48-72 hrs). Therefore, systems that maintain viability…2017 American Transplant Congress
Pre-Transplant Evaluation of KSORTSM to Assess Risk for Rejection in Highly Sensitized Patients.
Study purpose: To investigate the kSORTSM molecular expression assay for immune risk assessment in renal transplant (tx) recipients prior to tx for correlation of pre-tx…2017 American Transplant Congress
Desensitization versus Deceased Donor Kidney Transplantation: What to Choose When Both Become Available?
1UCSF, San Francisco; 2Johns Hopkins, Baltimore; 3NYU, New York
Kidney allocation system changes have improved deceased donor kidney transplant (DDKT) access for highly sensitized patients. For patients with a willing live donor but requiring…2017 American Transplant Congress
Extended Experience with Tocilizumab (Anti-IL6R) for Difficult to Desensitize (Des) Patients Awaiting HLA Incompatible Kidney Transplant.
Kidney Transplant, Cedars-Sinai Medical Center, LA, CA
INTRODUCTION: ~30% of HS patients fail to respond to DES with IVIG+rituximab. IL6/IL-6R signaling is critical for B-cell differentiation to plasmablasts and IgG production. Tocilizumab…2017 American Transplant Congress
Clinical Outcomes of ABO and HLA Incompatible Kidney Transplantation – Nationwide Cohort Study.
Background This is a nationwide cohort study to investigate the impact of anti-A/B antibody or donor specific anti-HLA antibody (HLA-DSA) on the clinical outcomes in…2017 American Transplant Congress
Update of a Placebo-Controlled Trial of C1 Esterase Inhibitor for Prevention of Antibody Mediated Rejection (ABMR) in Highly-HLA Sensitized Patients.
Kidney Transplant, Cedars-Sinai Medical Center, LA, CA
INTRODUCTION: Desensitization (DES) strategies focus primarily on antibody reduction using IVIG, rituximab ± PLEX to prevent DSA-induced ABMR and rebound B-cell activity. Pathologic features of…2017 American Transplant Congress
Assessing the Impact of the New KAS on Transplant Rates in Highly-HLA Sensitized (HS) Patients After Desensitization (Des) 2 Years Post Implementation.
Introduction: The new KAS aims to improve access to transplantation for HS patients, specifically CPRA 99-100%. Our center has extensive experience w. DES to improve…2017 American Transplant Congress
Three Year Outcomes Following Positive Crossmatch Renal Transplantation Despite Failure to Convert to Negative Flow Crossmatch After Desensitization.
Purpose: To determine outcomes of positive crossmatch (PXM) renal transplant recipients that failed to convert to a negative flow cytometry crossmatch (FCXM) despite desensitization. Methods:…2017 American Transplant Congress
Outcomes of 100 ABO Incompatible Kidney Transplants: A Single US Center Experience.
Comprehensive Transplant Center, Cedars-Sinai Medical Center, Los Angeles, CA
IntroductionAcceptable patient and graft outcomes of ABO incompatible (ABOi) living donor kidney transplantation (LDKT) have been reported with the use of desensitization strategies. Data on…2016 American Transplant Congress
Alemtuzumab Is Safe and Effective Induction Therapy in Highly Sensitized (HS) Pediatric Patients Undergoing Transplantation.
Introduction: Studies show that alemtuzumab, a potent lymphocyte-depleting agent, is well-tolerated in pediatric renal transplantation. We report on the use of alemtuzumab induction in HS…
- « Previous Page
- 1
- …
- 8
- 9
- 10
- 11
- 12
- …
- 15
- Next Page »